Latest Conference Articles

African Americans living in the poorest neighborhoods have double the risk of kidney transplant failure compared with white non-Hispanic patients.

Older adults with hyponatremia experience increased rates of fractures and falls, but are not at higher risk for osteoporosis.

Combo therapy with thiazide diuretics may be a major cause of symptomatic hyponatremia, especially in older females with prior cerebrovascular events.

Studies show tolvaptan treats significant dilutional hyponatremia and can improve patient performance in neurocognitive and gait tests.

Researchers continue to study the cardiovascular benefits associated with the DASH diet. Patients with CKD should adjust potassium intake.

Patients with chronic kidney disease treated by a nephrologist earlier in the care process face decreased risk of end-stage renal disease and death.

Study showing racial differences in rate of kidney function decline may point to new opportunities for kidney disease prevention.

Information on diagnostic and therapeutic approaches to hyponatremia, including tolvaptan and other VRAs, will be presented at this year's conference.

Evidence-based strategies can alleviate gaps in providers' knowledge of chronic kidney disease and diabetes in underserved patient populations.

Retrospective analysis reveals that statin use is not associated with increased risk of cancer.

Post-traumatic stress disorder more than doubles a veteran's risk of death from any cause and is an independent risk factor for cardiovascular disease.

Poor medication plan adherence poses major health risks in patients with cardiovascular illnesses. Better adherence starts with better communication.

Study shows that cholesteryl ester transfer protein (CETP) inhibitor anacetrapib reduced LDL by 40% and doubled HDL in patients with coronary disease.

GRAVITAS trial results show that high-dose clopidogrel does not reduce the incidence of death, heart attack, or blood clots in high-risk patients.

Once you've determined that a patient truly is statin-intolerant, there are several viable alternatives for lipid-lowering therapy, including niacin.

Intravenous treatment with the iron compound ferric carboxymaltose improves health-related quality of life in patients with chronic heart failure.

Unique treatment using fat-derived stem cells reduced heart tissue damage and improved cardiac blood flow in patients who had suffered a heart attack.

Alternate statin-dosing protocol shows significant reductions in LDL and total cholesterol in previously statin-intolerant women.

Researchers find no benefit from prescription omega-3 in patients with paroxysmal atrial fibrillation who do not have significant heart disease.

MESA trial finds association between lower coronary artery calcium and carotid artery thickness and adherence to AHA "Life's Simple 7" health factors.

Rivaroxaban is as effective as warfarin in preventing blood clots and stroke and does not increase bleeding risk in patients with atrial fibrillation.

Data from NHANES-III shows that vitamin D deficiency does not increase stroke risk in African American patients.

ASCEND-HF trial shows that previous thinking on nesiritide was wrong: it is safe, but has only modest effect on dyspnea patients with heart failure.

EMPHASIS-HF trial results show eplerenone reduces risk of death and hospitalization by 37% in patients with systolic heart failure.

Combining cardiac-resynchronization therapy with medication and an ICD reduces deaths and hospitalizations due to heart failure.

Scheduling, event, exhibit hall, CME, and other information for attendees of the AHA 2010 Scientific Sessions.

Consuming even one serving per day of sugar-sweetened soda or orange juice significantly increases the risk of developing gout.

Drug elevates lipid particles that are thought to be protective, leaves proatherogenic particles unchanged, and reduces markers of inflammation.

Osteoporosis guidelines and a Web-based tool allow physicians to identify patients for treatment and calculate 10-year fracture risk.

Study suggests that anti-tumor necrosis factor inhibitors may reduce the risk of developing Alzheimer's disease in patients with rheumatoid arthritis.